RT Journal Article
SR Electronic
T1 Novel Therapeutic Approaches for Epstein-Barr Virus Associated Gastric Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4003
OP 4010
DO 10.21873/anticanres.13555
VO 39
IS 8
A1 BYUNG WOOG KANG
A1 DONG WON BAEK
A1 HYOJEUNG KANG
A1 JIN HO BAEK
A1 JONG GWANG KIM
YR 2019
UL http://ar.iiarjournals.org/content/39/8/4003.abstract
AB Epstein-Barr virus (EBV)-associated gastric cancer (GC) (EBVaGC) is classified as one of four GC subtypes by comprehensive molecular characterization. Though the mechanism of tumorigenesis by EBV infection has not yet been fully clarified, EBV infection might contribute to the malignant transformation of GC cells by involving various cellular processes and signaling pathways. EBVaGC has shown the following distinct characteristics in contrast to other subtypes: extreme DNA hypermethylation, recurrent phosphatidylinositol 4,5-biphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) mutations, overexpression of programmed cell death ligand 1/2 (PD-L1/2), and occasional immune cell signaling activation. Therefore, using these molecular features as guides, targeted agents need to be evaluated in clinical trials for EBVaGC. Accordingly, this review uses the best available evidence to focus on novel therapeutic approaches using the distinct pathologic characteristics of EBVaGC patients.